A phase 3 trial of bevacizumab in ovarian cancer

Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédéric Selle, Mansoor R MirzaArto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh K B Parmar, Amit M Oza, ICON7 Investigators

    1696 Citationer (Scopus)

    Abstract

    Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.
    OriginalsprogEngelsk
    TidsskriftNew England Journal of Medicine
    Vol/bind365
    Udgave nummer26
    Sider (fra-til)2484-96
    Antal sider13
    ISSN0028-4793
    DOI
    StatusUdgivet - dec. 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'A phase 3 trial of bevacizumab in ovarian cancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater